Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC
Status:
COMPLETED
Trial end date:
2024-01-31
Target enrollment:
Participant gender:
Summary
This study aimed to investigate the combination of chemotherapy and immunotherapy for patients with metastatic ALK fusion-positive non-small cell lung cancer (NSCLC) who had failed from first line Alectinib. Additionally, available biological samples such as blood and tumor tissues were collected to explore potential biomarkers, including but not limited to RNA-seq, whole-exome sequencing (WES), whole-genome sequencing (WGS), immunohistochemistry, and multiplex immunofluorescence.
Phase:
PHASE2
Details
Lead Sponsor:
Hunan Province Tumor Hospital
Treatments:
Bevacizumab Drug Therapy Immune Checkpoint Inhibitors